Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
2.090 USD   +2.45%
12/01Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
AQ
11/29Affimed N : Presentation
PU
11/16Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/28/2022 11/29/2022 11/30/2022 12/01/2022 12/02/2022 Date
2.04(c) 1.99(c) 2.14(c) 2.04(c) 2.09 Last
1 894 519 1 069 117 2 402 772 725 369 2 196 883 Volume
-2.39% -2.45% +7.54% -4.67% +2.45% Change
More quotes
Estimated financial data (e)
Sales 2022 37,2 M 39,0 M 39,0 M
Net income 2022 -83,4 M -87,6 M -87,6 M
Net cash position 2022 188 M 197 M 197 M
P/E ratio 2022 -3,33x
Yield 2022 -
Sales 2023 31,7 M 33,2 M 33,2 M
Net income 2023 -126 M -132 M -132 M
Net cash position 2023 89,0 M 93,4 M 93,4 M
P/E ratio 2023 -2,41x
Yield 2023 -
Capitalization 290 M 305 M 305 M
EV / Sales 2022 2,75x
EV / Sales 2023 6,35x
Nbr of Employees 197
Free-Float 94,4%
More Financials
Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28... 
Sector
Biotechnology & Medical Research
Calendar
12/10 | 02:15pmPresentation
More about the company
Ratings of Affimed N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about AFFIMED N.V.
12/01Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annu..
AQ
11/29Affimed N : Presentation
PU
11/16Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and..
AQ
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15ETF Preview: ETFs, Stock Futures Rise Pre-Bell After Producer Price Index, M..
MT
11/15Transcript : Affimed N.V., Q3 2022 Earnings Call, Nov 15, 2022
CI
11/15Affimed Narrows Q3 Loss as Revenue Rises
MT
11/15Affimed N : Unaudited Condensed Consolidated Interim Financial Statements as of September ..
PU
11/15Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
11/15Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
11/15Affimed Reports Third Quarter 2022 Financial Results andáHighlights Recent Clinical and..
AQ
11/08Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AF..
AQ
11/07Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager A..
GL
11/07Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager A..
GL
11/04Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 1..
AQ
More news
News in other languages on AFFIMED N.V.
11/15Mise à jour sectorielle : Les actions du secteur de la santé son..
11/15Aperçu des ETF : Les ETF et les actions à terme augmentent avant la cloch..
11/15Affimed réduit sa perte au troisième trimestre et augmente ses revenus
11/15Affimed N.V. annonce ses résultats pour le troisième trimestre et les neuf mois terminé..
11/15Affimed N.V. annonce ses résultats pour le troisième trimestre et les neuf mois terminé..
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
ETFs positioned on AFFIMED N.V.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD0.56%0.55%United_States
ALPS Medical Breakthroughs ETF - USD0.25%1.56%United_States
IShares Micro-Cap ETF - USD0.09%1.22%United_States
Invesco Nasdaq Biotechnology ETF - USD0.03%2.39%-United_States
IShares Nasdaq US Biotechnology (D) - USD0.03%2.62%United_States
More ETFs positioned on AFFIMED N.V.
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 1,94 €
Average target price 9,26 €
Spread / Average Target 376%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Commercial Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.-63.04%320
VERTEX PHARMACEUTICALS46.07%81 217
REGENERON PHARMACEUTICALS, INC.19.03%80 283
BIONTECH SE-34.26%40 589
WUXI APPTEC CO., LTD.-32.53%32 137
GENMAB A/S25.29%29 594